Related references
Note: Only part of the references are listed.Linagliptin-Mediated DPP-4 Inhibition Ameliorates Kidney Fibrosis in Streptozotocin-Induced Diabetic Mice by Inhibiting Endothelial-to-Mesenchymal Transition in a Therapeutic Regimen
Keizo Kanasaki et al.
DIABETES (2014)
Blood pressure and glucose independent renoprotective effects of dipeptidyl peptidase-4 inhibition in a mouse model of type-2 diabetic nephropathy
Yuliya Sharkovska et al.
JOURNAL OF HYPERTENSION (2014)
Sitagliptin Prevents Inflammation and Apoptotic Cell Death in the Kidney of Type 2 Diabetic Animals
Catarina Marques et al.
MEDIATORS OF INFLAMMATION (2014)
Cardioprotective Effects of Exenatide in Patients With ST-Segment-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention Results of Exenatide Myocardial Protection in Revascularization Study
Jong Shin Woo et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2013)
Role of GLP-1 and DPP-4 in diabetic nephropathy and cardiovascular disease
Usha Panchapakesan et al.
CLINICAL SCIENCE (2013)
Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes
William B. White et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus
Benjamin M. Scirica et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Preventive Effects of Exenatide on Endothelial Dysfunction Induced by Ischemia-Reperfusion Injury via KATP Channels
Sang Jin Ha et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2012)
Dipeptidyl Peptidase IV Inhibitor Attenuates Kidney Injury in Streptozotocin-Induced Diabetic Rats
Wei Jing Liu et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2012)
Diabetic Nephropathy Amelioration by a Low-Dose Sitagliptin in an Animal Model of Type 2 Diabetes (Zucker Diabetic Fatty Rat)
Cristina Mega et al.
EXPERIMENTAL DIABETES RESEARCH (2011)
Genetic Deletion or Pharmacological Inhibition of Dipeptidyl Peptidase-4 Improves Cardiovascular Outcomes After Myocardial Infarction in Mice
Meghan Sauve et al.
DIABETES (2010)
Ser9 phosphorylation of mitochondrial GSK-3β is a primary mechanism of cardiomyocyte protection by erythropoietin against oxidant-induced apoptosis
Katsuhiko Ohori et al.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2008)
Inhibition of GSK3β by postconditioning is required to prevent opening of the mitochondrial permeability transition pore during reperfusion
Ludovic Gomez et al.
CIRCULATION (2008)
GLP-1 Therapy Beyond Glucose Control
Derek J. Hausenloy et al.
CIRCULATION-HEART FAILURE (2008)
The physiology of glucagon-like peptide 1
Jens Juul Holst
PHYSIOLOGICAL REVIEWS (2007)
Somatic events modify hypertrophic cardiomyopathy pathology and link hypertrophy to arrhythmia
CM Wolf et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Experimental diabetes and left ventricular hypertrophy -: Effects of beta-receptor blockade
D Grimm et al.
CARDIOVASCULAR PATHOLOGY (2002)
Myocardial cell death in human diabetes
A Frustaci et al.
CIRCULATION RESEARCH (2000)
Share Paper
